"Heart failure is a journey. We owe it to our patients to be the best possible guide for their well-being."
- Javed Butler, MD, MPH, MBA

A global heart failure curriculum centered on guidelines, evidence-based medicine & real-world data to improve patient outcomes in the management of heart failure.

Resources

Guidelines and Consensus Statements


National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018

NHFA CSANZ Heart Failure Guidelines Working Group, Atherton JJ, Sindone A, et al. Heart Lung Circ. 2018;27(10):1123-1208.

Expert Consensus Document on the Management of Hyperkalaemia in Patients with Cardiovascular Disease Treated with Renin Angiotensin Aldosterone System Inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Rosano GMC, Tamargo J, Kjeldsen KP, et al. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):180-188.

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Yancy CW, Jessup M, Bozkurt B, et al. J Am Coll Cardiol. 2017;70(6):776-803.

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC

Ponikowski P, Voors AA, Anker SD, et al. Eur J Heart Fail. 2016;37(27):2129-2200.

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Yancy CW, Jessup M, Bozkurt B, et al. J Am Coll Cardiol. 2016;68(13):1476-1488.

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Yancy CW, Jessup M, et al. Circulation. 2013;128(16):e240-e327.




CLINICAL ARTICLES

Heart Failure Management


Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients with Heart Failure with Reduced Ejection Fraction: A Comparative Analysis of Three Randomised Controlled Trials

Vaduganathan M, Claggett BL, Jhund PS, et al. Lancet. 2020; 396(10244):121-128.

Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure Registry

Savarese G, Carrero JJ, Pitt B, et al. Eur J Heart Fail. 2018;20(9):1326-1334.

Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry

Greene SJ, Butler J, Albert NM et al. J Am Coll Cardiol. 2018;72(4):351-366.

Association Between Enrolment in a Heart Failure Quality Registry and Subsequent Mortality—A Nationwide Cohort Study

Lund LH, Carrero JJ, Farahmand B, et al. Eur J Heart Fail. 2017;19(9):1107–1116.

European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year Follow-up Outcomes and Differences Across Regions

Crespo-Leiro MG, Anker SD, Maggioni AP, et al. Eur J Heart Fail. 2016;18(6):613-625.

Physicians' Adherence to Guideline-recommended Medications in Heart Failure with Reduced Ejection Fraction: Data from the QUALIFY Global Survey

Komajda M, Anker SD, Cowie MR, et al. Eur J Heart Fail. 2016;18(5):514-522.

Efficacy and Safety of Exercise Training in Patients with Chronic Heart Failure: HF-ACTION Randomized Controlled Trial.

O'Connor CM, Whellan DJ, Lee KL, et al. JAMA. 2009;301(14):1439-1450.

Use of Aldosterone Antagonists in Heart Failure

Albert NM, Yancy CW, Liang L, et al. JAMA. 2009;302(15):1658-1665.

Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings from OPTIMIZE-HF

Fonarow GC, Abraham WT, Albert NM, et al. Arch Intern Med. 2008;168(8):847-854.

Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings from IMPROVE HF

Fonarow GC, Yancy CW, Albert NM, et al. Circ Heart Fail. 2008;1(2):98-106.




Hyperkalemia


Unravelling the Interplay Between Hyperkalaemia, Renin-angiotensin-aldosterone Inhibitor Use and Clinical Outcomes: Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

Rossignol P, Lainscak M, Crespo-Leiro MG, et al. Eur J Heart Fail. Published online April 3, 2020. doi:10.1002/ejhf.1793

Association Between Potassium Level and Outcomes in Heart Failure with Reduced Ejection Fraction: A Cohort Study from the Swedish Heart Failure Registry

Cooper LB, Benson L, Mentz RJ, et al. Eur J Heart Fail. Published online February 20, 2020. doi:10.1002/ejhf.1757

Cardiovascular Risk Associated with Serum Potassium in the Context of Mineralocorticoid Receptor Antagonist Use in Patients with Heart Failure and Left Ventricular Dysfunction

Rossignol P, Duarte K, Girerd N, et al. Eur J Heart Fail. Published online January 9, 2020. doi:10.1002/ejhf.1724

Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review

Ferreira JP, Butler J, Rossignol P, et al. J Am Coll Cardiol. 2020;75(22):2836-2850.

Daily Home Monitoring of Potassium, Creatinine, and Estimated Plasma Volume in Heart Failure Post-discharge.

Rossignol P, Fay R, Girerd N, Zannad F. ESC Heart Fail. 2020;7(3):1257-1263

Patiromer Sorbitex Calcium for Hyperkalaemia

Aust Prescr. 2020;43(1):28-29.

Recurrent Hyperkalaemia Management and Use of Renin–angiotensin–aldosterone System Inhibitors: A European Multi-national Targeted Chart Review

Rossignol P, Ruilope LM, Cupisti A, et al. Clin Kidney J. Published online September 30, 2019. doi:10.1093/ckj/sfz129

Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE

Roger SD, Spinowitz BS, Lerma EV, et al. Am J Nephrol. 2019;50(6):473-480.

Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial

Agarwal R, Rossignol P, Romero A, et al. Lancet. 2019;394(10208):1540-1550.

Sodium Zirconium Cyclosilicate Among Individuals with Hyperkalemia: A 12-month Phase 3 Study

Spinowitz BS, Fishbane S, Pergola PE, et al. Clin J Am Soc Nephrol. 2019;14(6):798-809.

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors

Weir MR, Bushinsky DA, Benton WW, et al. Am J Med. 2018;131(5):555-564.e3.

Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN

Pitt B, Bakris GL, Weir MR, et al. ESC Heart Fail. 2018;5(4):592-602.

Potassium and the Use of Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data From BIOSTAT-CHF

Beusekamp JC, Tromp J, van der Wal HH, et al. Eur J Heart Fail. 2018;20(5):923-930.

Hyperkalemia in Heart Failure

Sarwar CMS, Papadimitriou L, Pitt B, et al. J Am Coll Cardiol. 2016;68(14):1575-1589.

Effect of Patiromer on Serum Potassium Level in Patients with Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Bakris GL, Pitt B, Weir MR, et al. JAMA. 2015;314(2):151-161.

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Weir MR, Bakris GL, Bushinsky DA, et al. N Engl J Med. 2015;372(3):211-221.

Maintenance of Serum Potassium with Sodium Zirconium Cyclosilicate (ZS-9) in Heart Failure Patients: Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

Anker SD, Kosiborod M, Zannad F, et al. Eur J Heart Fail. 2015;17(10):1050-1056.

Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients with Hyperkalemia: The HARMONIZE Randomized Clinical Trial

Kosiborod M, Rasmussen HS, Lavin P, et al. JAMA. 2014;312(21):2223-2233.




Iron Deficiency


Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction

Alcaide-Aldeano A, Garay A, Alcoberro L, et al. J Clin Med. 2020;9(4):1199.

Iron Deficiency in Heart Failure: An Overview

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. JACC Heart Fail. 2019;7(1):36-46.

Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient Data Meta-Analysis

Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Eur J Heart Fail. 2018;20(1):125-133.

Screening, Diagnosis and Treatment of Iron Deficiency in Chronic Heart Failure: Putting the 2016 European Society of Cardiology Heart Failure Guidelines into Clinical Practice

McDonagh T, Damy T, Doehner W, et al. Eur J Heart Fail. 2018;20(12):1664-1672.

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency

van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Circulation. 2017;136(15):1374-1383.

Beneficial Effects of Long-Term Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Eur Heart J. 2015;36(11):657-668.

High Prevalence of Iron Deficiency in Patients with Acute Decompensated Heart Failure

Cohen-Solal A, Damy T, Terbah M, et al. Eur J Heart Fail. 2014;16(9):984-991.

Iron Deficiency in Chronic Heart Failure: An International Pooled Analysis

Klip IT, Comin-Colet J, Voors AA, et al. Am Heart J. 2013;165(4):575-582.e3.

Iron Deficiency Is a Key Determinant of Health-Related Quality of Life in Patients with Chronic Heart Failure Regardless of Anaemia Status

Comín‐Colet J, Enjuanes C, González G, et al. Eur J Heart Fail. 2013;15(10):1164-1172.

Iron Status in Patients with Chronic Heart Failure

Jankowska EA, Malyszko J, Ardehali H, et al. Eur Heart J. 2013;34(11):827-834.

Iron Deficiency Predicts Impaired Exercise Capacity in Patients with Systolic Chronic Heart Failure

Jankowska EA, Rozentryt P, Witkowska A, et al. J Card Fail. 2011;17(11):899-906.

Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

Anker SD, Comin Colet J, Filippatos G, et al. N Engl J Med. 2009;361(25):2436-2448.




Downloadable Slides and Resources


Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency

Slides from an expert interview exploring the evidence behind screening for iron deficiency in heart failure and how its treatment can alleviate heart failure symptoms.

Don’t Be Fooled: It’s Iron Deficiency, Not Just Anemia

Slides from a podcast discussing when patients with heart failure should be screened and how to best treat those with iron deficiency.

Examining Heart Failure Management: Can We Be Doing Better?

Slides from a panel discussion on heart failure guidelines.

Potassium and Heart Failure

An educational handout for patients on dietary considerations surrounding potassium and heart failure.

Potassium Management

A clinical guide for potassium binder use and mineralocorticoid receptor antagonist dose adjustments in response to serum potassium values.

Potassium Binders in Heart Failure: Who, When, and How

Slides from a podcast exploring potassium monitoring strategies and how to best utilize novel potassium binders for maximum guideline-recommended RAASi therapy.



Helpful Websites